Discovery of Capsazepine as a Novel MCL1 Inhibitor for Overcoming Tamoxifen Resistance in Breast Cancer Therapy
Authors:
Open Access
Abstract
Tamoxifen resistance remains a significant clinical challenge in breast cancer. The anti‐apoptotic protein MCL1 is frequently overexpressed in tamoxifen‐resistant tumors and is associated with poor patient survival, underscoring its potential as a therapeutic target. To identify novel MCL1 inhibitors, we first confirmed MCL1 upregulation in tamoxifen‐resistant MCF7‐R cells and clinical specimens. Using high‐throughput virtual screening, molecular docking, and dynamics simulations, we identified capsazepine (CPZ) as a promising candidate. CPZ exhibited high binding affinity and formed stable interactions with key MCL1 residues, LEU267 and PHE270. Experimentally, CPZ significantly suppressed proliferation and induced mitochondrial‐dependent apoptosis in MCF7‐R cells. Importantly, CPZ synergized with tamoxifen to suppress colony formation and promote apoptosis, effectively reversing the resistant phenotype. Mechanistic studies using Drug Affinity Responsive Target Stability (DARTS) and functional assays confirmed that CPZ directly binds to and stabilizes MCL1. CPZ also demonstrated favorable drug‐like properties and a superior predicted toxicity profile compared to the established inhibitor UMI‐77. Our findings establish CPZ as a novel and effective MCL1 inhibitor that can help overcome tamoxifen resistance, offering a promising combined therapeutic strategy for endocrine‐resistant breast cancer.Keywords
Funding Information
- National Natural Science Foundation of China (32371153)
- National Natural Science Foundation of China (31770968)
- National Natural Science Foundation of China (31800661)
This publication has 47 references indexed in Scilit:
- USP46 enhances tamoxifen resistance in breast cancer cells by stabilizing PTBP1 to facilitate glycolysisBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2024
- EGR3 and estrone are involved in the tamoxifen resistance and progression of breast cancerJournal of Cancer Research and Clinical Oncology, 2023
- Discovery of Mcl-1 inhibitors through virtual screening, molecular dynamics simulations and in vitro experimentsComputers in Biology and Medicine, 2022
- Drug affinity responsive target stability (DARTS) accelerated small molecules target discovery: Principles and applicationBiochemical Pharmacology, 2021
- Metabolic reprograming confers tamoxifen resistance in breast cancerChemico-Biological Interactions, 2021
- Overcoming Endocrine Resistance in Breast CancerCancer Cell, 2020
- Targeting MCL-1 in hematologic malignancies: Rationale and progressBlood Reviews, 2020
- A Redox‐Triggered Bispecific Supramolecular Nanomedicine Based on Peptide Self‐Assembly for High‐Efficacy and Low‐Toxic Cancer TherapyAdvanced Functional Materials, 2019
- Hesperidin, piperine and bee venom synergistically potentiate the anticancer effect of tamoxifen against breast cancer cellsBiomedicine & Pharmacotherapy, 2018
- The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedCancer Cell, 2006